{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T17:39:21Z","timestamp":1715794761264},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00508-016-0993-x","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T17:51:08Z","timestamp":1459965068000},"page":"216-228","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications"],"prefix":"10.1007","volume":"128","author":[{"given":"Hermann","family":"Toplak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Ludvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Lechleitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Dieplinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"F\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Paulweber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Watschinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Wascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Pilger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erich","family":"Pohanka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Traindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz Xaver","family":"Roithinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Haring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kiechl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"993_CR1","first-page":"1","volume":"Suppl 4","author":"J Willeit","year":"2014","unstructured":"Willeit J, Kiechl S, et\u00a0al. Positionspapier der \u00d6GSF \u2013 Update 2014: Akutmanagement und Sekund\u00e4rpr\u00e4vention des Schlaganfalls. neurologisch. 2014;Suppl 4:1\u201323, http:\/\/www.oegsf.at\/aerzte\/uploads\/Positionspapiere\/OEGSF%20Positionspapier%202014.pdf .","journal-title":"neurologisch"},{"key":"993_CR2","first-page":"\u25a0","volume":"\u25a0","author":"M Brodmann","year":"2012","unstructured":"Brodmann M, et\u00a0al. Positionspapier Lipidtherapie in der Angiologie. MEDahead. 2012, http:\/\/www.medmedia.at\/pos-lipide . Last accessed: February 29, 2016.","journal-title":"MEDahead"},{"key":"993_CR3","first-page":"\u25a0","volume":"\u25a0","author":"M Brodmann","year":"2013","unstructured":"Brodmann M, Gremmel T, Huber J, et\u00a0al. Positionspapier Management von Patienten mit Gef\u00e4\u00dferkrankungen und Diabetes mellitus. MEDahead. 2013, http:\/\/www.medmedia.at\/pos-diabetes . Last accessed: February 29, 2016.","journal-title":"MEDahead"},{"issue":"Suppl 2","key":"993_CR4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00508-012-0273-3","volume":"124","author":"TC Wascher","year":"2012","unstructured":"Wascher TC, Paulweber B, Toplak H, et\u00a0al. Lipide: Diagnostik und Therapie bei Diabetes mellitus Typ 2. Wien Klin Wochenschr. 2012;124(Suppl 2):28\u201330.","journal-title":"Wien Klin Wochenschr"},{"key":"993_CR5","volume-title":"\u00d6sterreichischer Lipidkonsensus 2010. Management von Fettstoffwechselst\u00f6rungen zur Pr\u00e4vention vaskul\u00e4rer Komplikationen","author":"H Toplak","year":"2010","unstructured":"Toplak H. et\u00a0al. \u00d6sterreichischer Lipidkonsensus 2010. Management von Fettstoffwechselst\u00f6rungen zur Pr\u00e4vention vaskul\u00e4rer Komplikationen. : MedMedia Verlag; 2010, http:\/\/www.oedg.org\/pdf\/Lipidkonsensus_2010.pdf . Last accessed: February 29, 2016."},{"issue":"19","key":"993_CR6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486\u20132497.","journal-title":"JAMA"},{"issue":"2","key":"993_CR7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et\u00a0al. American college of cardiology foundation; american heart association. implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110(2):227\u2013239.","journal-title":"Circulation"},{"issue":"14","key":"993_CR8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et\u00a0al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769\u20131818.","journal-title":"Eur Heart J"},{"issue":"13","key":"993_CR9","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, et\u00a0al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). the fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635\u20131701.","journal-title":"Eur Heart J"},{"issue":"32","key":"993_CR10","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, et\u00a0al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u20132157.","journal-title":"Eur Heart J"},{"issue":"7","key":"993_CR11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/2047487314533218","volume":"22","author":"GF Watts","year":"2015","unstructured":"Watts GF, Gidding S, Wierzbicki AS, et\u00a0al. Integrated guidance on the care of familial hypercholesterolaemia from the international FH foundation. Eur J Prev Cardiol. 2015;22(7):849\u2013854.","journal-title":"Eur J Prev Cardiol"},{"issue":"25 Suppl 2","key":"993_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et\u00a0al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology\/american heart association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):1\u201345.","journal-title":"Circulation"},{"issue":"11","key":"993_CR13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy RM, Py\u00f6r\u00e4l\u00e4 K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987\u20131003.","journal-title":"Eur Heart J"},{"issue":"18","key":"993_CR14","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, et\u00a0al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837\u20131847.","journal-title":"Circulation"},{"issue":"6","key":"993_CR15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"2","key":"993_CR16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434\u2013434.","journal-title":"Diabetes Care"},{"issue":"6797","key":"993_CR17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/bmj.303.6797.276","volume":"303","author":"Z Chen","year":"1991","unstructured":"Chen Z, Peto R, Collins R, et\u00a0al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303(6797):276\u2013282.","journal-title":"BMJ"},{"issue":"9493","key":"993_CR18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u20131278.","journal-title":"Lancet"},{"issue":"9841","key":"993_CR19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u2013590.","journal-title":"Lancet"},{"issue":"23","key":"993_CR20","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","volume":"117","author":"JJ Kastelein","year":"2008","unstructured":"Kastelein JJ, van der Steeg WA, Holme I, et\u00a0al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002\u20133009.","journal-title":"Circulation"},{"issue":"21","key":"993_CR21","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","volume":"166","author":"P Thavendiranathan","year":"2006","unstructured":"Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166(21):2307\u20132313.","journal-title":"Arch Intern Med"},{"issue":"15","key":"993_CR22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et\u00a0al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u20131504.","journal-title":"N Engl J Med"},{"issue":"2","key":"993_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139\u2013151.","journal-title":"J Clin Pharm Ther"},{"issue":"9716","key":"993_CR24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u2013742.","journal-title":"Lancet"},{"issue":"24","key":"993_CR25","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556\u20132564.","journal-title":"JAMA"},{"key":"993_CR26","first-page":"346","volume":"2610","author":"AA Carter","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, et\u00a0al. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;2610:346.","journal-title":"BMJ"},{"issue":"14","key":"993_CR27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2012.05.019","volume":"60","author":"KL Wang","year":"2012","unstructured":"Wang KL, Liu CJ, Chao TF, et\u00a0al. Statins, risk of diabetes, and implications on outcomes in the general population. J\u00a0Am Coll Cardiol. 2012;60(14):1231\u20131238.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"993_CR28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","volume":"58","author":"H Cederberg","year":"2015","unstructured":"Cederberg H, Stan\u010d\u00e1kov\u00e1 A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58(5):1109\u20131117.","journal-title":"Diabetologia"},{"issue":"21","key":"993_CR29","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","volume":"105","author":"C Gagn\u00e9","year":"2002","unstructured":"Gagn\u00e9 C, Gaudet D, Bruckert E, et\u00a0al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105(21):2469\u20132475.","journal-title":"Circulation"},{"issue":"8","key":"993_CR30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0195-668X(02)00803-5","volume":"24","author":"L Melani","year":"2003","unstructured":"Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003;24(8):717\u2013728.","journal-title":"Eur Heart J"},{"issue":"19","key":"993_CR31","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","volume":"107","author":"CM Ballantyne","year":"2003","unstructured":"Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409\u20132415.","journal-title":"Circulation"},{"issue":"4","key":"993_CR32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1742-1241.2009.02022.x","volume":"63","author":"M Farnier","year":"2009","unstructured":"Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe\/simvastatin 10\/20\u202fmg compared with rosuvastatin 10\u202fmg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy \u2013 The IN-CROSS study. Int J Clin Pract. 2009;63(4):547\u2013559.","journal-title":"Int J Clin Pract"},{"issue":"9","key":"993_CR33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-151-9-200911030-00144","volume":"151","author":"M Sharma","year":"2009","unstructured":"Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med. 2009;151(9):622\u2013630.","journal-title":"Ann Intern Med"},{"issue":"9784","key":"993_CR34","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u20132192.","journal-title":"Lancet"},{"issue":"25","key":"993_CR35","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et\u00a0al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u20132397.","journal-title":"N Engl J Med"},{"issue":"15","key":"993_CR36","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1517\/14656566.8.15.2569","volume":"8","author":"MH Davidson","year":"2007","unstructured":"Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007;8(15):2569\u20132578.","journal-title":"Expert Opin Pharmacother"},{"key":"993_CR37","first-page":"CD009361","volume":"12","author":"CP Ooi","year":"2012","unstructured":"Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2012;12:CD009361.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"993_CR38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","volume":"45","author":"RS Birjmohun","year":"2005","unstructured":"Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185\u2013197.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"993_CR39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1185\/030079906X89865","volume":"22","author":"S Allemann","year":"2006","unstructured":"Allemann S, Diem P, Egger M, et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin. 2006;22(3):617\u2013623.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"993_CR40","doi-asserted-by":"crossref","first-page":"962.e1","DOI":"10.1016\/j.amjmed.2009.03.030","volume":"122","author":"S Abourbih","year":"2009","unstructured":"Abourbih S, Filion KB, Joseph L, et\u00a0al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;122(10):962.e1\u2013962.e8.","journal-title":"Am J Med"},{"issue":"9500","key":"993_CR41","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u20131861.","journal-title":"Lancet"},{"issue":"3","key":"993_CR42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","volume":"32","author":"R Scott","year":"2009","unstructured":"Scott R, O\u2019Brien R, Fulcher G, et\u00a0al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493\u2013498.","journal-title":"Diabetes Care"},{"issue":"17","key":"993_CR43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, et\u00a0al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u20131574.","journal-title":"N Engl J Med"},{"issue":"6","key":"993_CR44","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","volume":"91","author":"HE Bays","year":"2003","unstructured":"Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003;91(6):667\u2013672.","journal-title":"Am J Cardiol"},{"issue":"6","key":"993_CR45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"PL Canner","year":"1986","unstructured":"Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245\u20131255.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"993_CR46","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","volume":"323","author":"G Brown","year":"1990","unstructured":"Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(19):1289\u20131298.","journal-title":"N Engl J Med"},{"issue":"22","key":"993_CR47","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","volume":"345","author":"BG Brown","year":"2001","unstructured":"Brown BG, Zhao XQ, Chait A, et\u00a0al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583\u20131592.","journal-title":"N Engl J Med"},{"issue":"24","key":"993_CR48","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"AIM-HIGH Investigators","year":"2011","unstructured":"Investigators AIM-HIGH, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u20132267.","journal-title":"N Engl J Med"},{"issue":"17","key":"993_CR49","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","unstructured":"HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279\u20131291.","journal-title":"Eur Heart J"},{"issue":"3","key":"993_CR50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group, Landray MJ, Haynes. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u2013212.","journal-title":"N Engl J Med"},{"issue":"3","key":"993_CR51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJMe1406410","volume":"371","author":"DM Lloyd-Jones","year":"2014","unstructured":"Lloyd-Jones DM. Niacin and HDL cholesterol \u2013 time to face facts. N Engl J Med. 2014;371(3):271\u2013273.","journal-title":"N Engl J Med"},{"key":"993_CR52","volume-title":"Release EMA\/779546\/2013","author":"European Medicines Agency","year":"2013","unstructured":"European Medicines Agency. Release EMA\/779546\/2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Nicotinic_acid_31\/Position_provided_by_CMDh\/WC500158704.pdf ."},{"key":"993_CR53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2015.02.005","volume":"18","author":"I Gouni-Berthold","year":"2015","unstructured":"Gouni-Berthold I, Berthold HK. Mipomersen and lomitapide: two new drugs for the treatment of homozygous familial hypercholesterolemia. Atheroscler Suppl. 2015;18:28\u201334.","journal-title":"Atheroscler Suppl"},{"issue":"11","key":"993_CR54","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/13543784.2013.822485","volume":"22","author":"P Lee","year":"2013","unstructured":"Lee P, Hegele RA. Current Phase II proprotein convertase subtilisin\/kexin 9 inhibitor therapies for dyslipidemia. Expert Opin Investig Drugs. 2013;22(11):1411\u20131423.","journal-title":"Expert Opin Investig Drugs"},{"issue":"16","key":"993_CR55","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et\u00a0al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20131509.","journal-title":"N Engl J Med"},{"issue":"16","key":"993_CR56","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et\u00a0al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u20131499.","journal-title":"N Engl J Med"},{"issue":"12","key":"993_CR57","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/1060028015608487","volume":"49","author":"CM White","year":"2015","unstructured":"White CM. Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and alirocumab. Ann Pharmacother. 2015;49(12):1327\u20131335.","journal-title":"Ann Pharmacother"},{"issue":"18","key":"993_CR58","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1161\/CIRCULATIONAHA.113.002500","volume":"129","author":"C Stegemann","year":"2014","unstructured":"Stegemann C, Pechlaner R, Willeit P, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014;129(18):1821\u20131831.","journal-title":"Circulation"},{"issue":"9726","key":"993_CR59","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634\u20131639.","journal-title":"Lancet"},{"issue":"1","key":"993_CR60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"993_CR61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32\u201341.","journal-title":"N Engl J Med"},{"issue":"23","key":"993_CR62","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"371","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, et\u00a0al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200\u20132206.","journal-title":"N Engl J Med"},{"issue":"5","key":"993_CR63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C\u2011III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438\u2013447.","journal-title":"N Engl J Med"},{"issue":"10002","key":"993_CR64","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386(10002):1472\u20131483.","journal-title":"Lancet"},{"issue":"20","key":"993_CR65","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u20132619.","journal-title":"Eur Heart J"},{"issue":"9602","key":"993_CR66","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"S Lewington","year":"2007","unstructured":"Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829\u20131839.","journal-title":"Lancet"},{"issue":"5","key":"993_CR67","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"P Amarenco","year":"2009","unstructured":"Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453\u2013463.","journal-title":"Lancet Neurol."},{"issue":"6","key":"993_CR68","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","volume":"355","author":"P Amarenco","year":"2006","unstructured":"Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559.","journal-title":"N Engl J Med"},{"issue":"12","key":"993_CR69","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","volume":"38","author":"P Amarenco","year":"2007","unstructured":"Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke; a Journal of Cerebral Circulation. 2007;38(12):3198\u20133204.","journal-title":"Stroke; a Journal of Cerebral Circulation"},{"issue":"13","key":"993_CR70","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehn232","volume":"29","author":"P Amarenco","year":"2008","unstructured":"Amarenco P, Steg PG. Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention. Eur Heart J. 2008;29(13):1605\u20131607.","journal-title":"Eur Heart J"},{"issue":"18","key":"993_CR71","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIRCULATIONAHA.109.921072","volume":"121","author":"MS Dhamoon","year":"2010","unstructured":"Dhamoon MS, Elkind MS. Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease. Circulation. 2010;121(18):2071\u20132078.","journal-title":"Circulation"},{"issue":"1","key":"993_CR72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","volume":"42","author":"KL Furie","year":"2011","unstructured":"Furie KL, Kasner SE, Adams RJ, et\u00a0al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke; a Journal of Cerebral Circulation. 2011;42(1):227\u2013276.","journal-title":"Stroke; a Journal of Cerebral Circulation"},{"issue":"5","key":"993_CR73","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/STROKEAHA.110.605923","volume":"42","author":"A Biffi","year":"2011","unstructured":"Biffi A, Devan WJ, Anderson CD, et al. Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke. 2011;42(5):1314\u20131319.","journal-title":"Stroke"},{"issue":"9","key":"993_CR74","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/01.wnl.0000269789.09277.47","volume":"69","author":"M Blanco","year":"2007","unstructured":"Blanco M, Nombela F, Castellanos M, et\u00a0al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69(9):904\u2013910.","journal-title":"Neurology"},{"issue":"1","key":"993_CR75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/STROKEAHA.111.627729","volume":"43","author":"AC Flint","year":"2012","unstructured":"Flint AC, Kamel H, Navi BB, et\u00a0al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43(1):147\u2013154.","journal-title":"Stroke"},{"issue":"9","key":"993_CR76","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.0b013e31822c9135","volume":"77","author":"ST Engelter","year":"2011","unstructured":"Engelter ST, Soinne L, Ringleb P, et\u00a0al. IV thrombolysis and statins. Neurology. 2011;77(9):888\u2013895.","journal-title":"Neurology"},{"issue":"10","key":"993_CR77","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMoa0808207","volume":"361","author":"O Schouten","year":"2009","unstructured":"Schouten O, Boersma E, Hoeks SE, et\u00a0al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361(10):980\u2013989.","journal-title":"N Engl J Med"},{"issue":"2","key":"993_CR78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archsurg.2011.897","volume":"147","author":"V Chopra","year":"2012","unstructured":"Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg. 2012;147(2):181\u2013189.","journal-title":"Arch Surg."},{"issue":"5","key":"993_CR79","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jvs.2004.01.004","volume":"39","author":"AE Durazzo","year":"2004","unstructured":"Durazzo AE, Machado FS, Ikeoka DT, et\u00a0al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J\u00a0Vasc Surg. 2004;39(5):967\u2013976.","journal-title":"J Vasc Surg"},{"issue":"9326","key":"993_CR80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"issue":"5","key":"993_CR81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(03)00010-X","volume":"114","author":"S Mondillo","year":"2003","unstructured":"Mondillo S, Ballo P, Barbati R, et\u00a0al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114(5):359\u2013364.","journal-title":"Am J Med"},{"issue":"12","key":"993_CR82","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","volume":"108","author":"ER Mohler","year":"2003","unstructured":"Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481\u20131486.","journal-title":"Circulation"},{"issue":"1","key":"993_CR83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","volume":"217","author":"AL Catapano","year":"2011","unstructured":"Catapano AL, Reiner Z, De Backer G, et\u00a0al. ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the Euroean society of cardiology (ESC) and the european atherosclerosis society (EAS). Atherosclerosis. 2011;217(1):3\u201346.","journal-title":"Atherosclerosis."},{"issue":"39","key":"993_CR84","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the european society of cardiology (ESC) and developed in collaboration with the european association for the study of diabetes (EASD). Eur Heart J. 2013;34(39):3035\u20133087.","journal-title":"Eur Heart J"},{"key":"993_CR85","unstructured":"International Diabetes Federation, 2005. Available from: http:\/\/www.idf.org\/metabolic-syndrome ."},{"issue":"4","key":"993_CR86","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2337\/diacare.29.04.06.dc05-2011","volume":"29","author":"CH Saely","year":"2006","unstructured":"Saely CH, Koch L, Schmid F, et\u00a0al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care. 2006;29(4):901\u2013907.","journal-title":"Diabetes Care"},{"issue":"5","key":"993_CR87","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2337\/dc06-1484","volume":"30","author":"PC Tong","year":"2007","unstructured":"Tong PC, Kong AP, So WY, et\u00a0al. The usefulness of the international diabetes federation and the national cholesterol education program\u2019s adult treatment panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care. 2007;30(5):1206\u20131211.","journal-title":"Diabetes Care"},{"issue":"14","key":"993_CR88","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacc.2010.05.034","volume":"56","author":"S Mottillo","year":"2010","unstructured":"Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113\u20131132.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"993_CR89","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"HB Rubins","year":"1999","unstructured":"Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med. 1999;341(6):410\u2013418.","journal-title":"N Engl J Med"},{"issue":"2","key":"993_CR90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"39","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, et\u00a0al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;39(2):137\u2013147.","journal-title":"Ann Intern Med"},{"issue":"17","key":"993_CR91","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, et\u00a0al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154\u20132169.","journal-title":"Circulation"},{"issue":"5","key":"993_CR92","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","volume":"110","author":"EM Antman","year":"2004","unstructured":"Antman EM, Anbe DT, Armstrong PW, et al. ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction \u2013 executive summary: a report of the american college of cardiology\/american heart association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation. 2004;110(5):588\u2013636.","journal-title":"Circulation"},{"key":"993_CR93","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl. 2013;3(3):259\u2013305."},{"issue":"3","key":"993_CR94","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","volume":"160","author":"M Tonelli","year":"2014","unstructured":"Tonelli M, Wanner C. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2014;160(3):182.","journal-title":"Ann Intern Med"},{"issue":"3","key":"993_CR95","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, et\u00a0al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u2013248.","journal-title":"N Engl J Med"},{"issue":"14","key":"993_CR96","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, et\u00a0al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u20131407.","journal-title":"N Engl J Med"},{"issue":"9374","key":"993_CR97","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","volume":"361","author":"H Holdaas","year":"2003","unstructured":"Holdaas H, Fellstr\u00f6m B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024\u20132031.","journal-title":"Lancet"},{"issue":"2","key":"993_CR98","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2011.06.016","volume":"218","author":"OS Descamps","year":"2011","unstructured":"Descamps OS, Tenoutasse S, Stephenne X, et\u00a0al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218(2):272\u2013280.","journal-title":"Atherosclerosis"},{"issue":"Suppl 6A","key":"993_CR99","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1016\/j.amjmed.2004.02.006","volume":"116","author":"P Libby","year":"2004","unstructured":"Libby P, Ridker PM. Inflammation and atherosclerosis: role of C\u2011reactive protein in risk assessment. Am J Med. 2004;116(Suppl 6A):9S\u201316S.","journal-title":"Am J Med"},{"issue":"9","key":"993_CR100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","volume":"98","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Rifai N, Pfeffer MA, et\u00a0al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98(9):839\u2013844.","journal-title":"Circulation"},{"issue":"1","key":"993_CR101","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al. C\u2011reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"993_CR102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","volume":"114","author":"DA Morrow","year":"2006","unstructured":"Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C\u2011reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation. 2006;114(4):281\u2013288.","journal-title":"Circulation"},{"issue":"9","key":"993_CR103","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1185\/03007995.2014.924488","volume":"30","author":"VG Athyros","year":"2014","unstructured":"Athyros VG, Katsiki N, Karagiannis A, et\u00a0al. The 2013 American College of Cardiology\/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps! Curr Med Res Opin. 2014;30(9):1701\u20131705.","journal-title":"Curr Med Res Opin"},{"issue":"5\u20136","key":"993_CR104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00508-014-0513-9","volume":"126","author":"G Klose","year":"2014","unstructured":"Klose G, Beil FU, Dieplinger H, et\u00a0al. New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. Wien Klin Wochenschr. 2014;126(5\u20136):169\u2013175.","journal-title":"Wien Klin Wochenschr"},{"issue":"15","key":"993_CR105","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","volume":"35","author":"KK Ray","year":"2014","unstructured":"Ray KK, Kastelein JJ, Boekholdt SM, et\u00a0al. The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good, the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35(15):960.","journal-title":"Eur Heart J"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-0993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-016-0993-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-0993-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T07:16:14Z","timestamp":1600413374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-016-0993-x"}},"subtitle":["A\u00a0joint position statement issued by eight medical societies. 2016\u00a0update"],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":105,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s00508-016-0993-x","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}